Ridge Diagnostics, Inc. Clinical Data on Blood Test for Depression Presented at American Psychological Association Annual Meeting
Published: May 21, 2009
SAN DIEGO, May 20 /PRNewswire/ -- Ridge Diagnostics, Inc., a neurodiagnostic company, announced that data from clinical studies for its first-in-class, proprietary blood test for Major Depressive Disorder(MDD), will be presented during a poster session entitled Multianalyte Biomarker Blood Test to Aid in Diagnosis, Treatment and Management of Major Depressive Disorder, at the American Psychiatric Association Annual Meeting, May 20, 2009.
The blood test, for the first time, provides clinicians with biological information derived from physiological changes associated with MDD. By adding an objective, biological basis, the blood test results are intended to augment the paradigm used for neuropsychiatric diagnosis and patient management, primarily clinical interviews. Our approach differs from other investigators seeking to utilize single or groups of single biomarkers to characterize or identify patients with MDD by use of multiple markers and the construction of a unique diagnostic hyperspace mapping technology.
"We are pleased to present this clinically important blood test to the psychiatric community at the APA meeting," stated Stan Sewitch, President and CEO of Ridge. "We believe the assay results provide an objective adjunct to a patient's diagnosis and management, while at the same time providing the research community with a valuable tool for optimization of studies."
The poster will be presented by Dr. Perry Renshaw, Chief Medical Officer of Ridge Diagnostics and Director of Magnetic Resonance, Utah Brain Institute, Professor of Psychiatry, University of Utah School of Medicine.
Ridge Diagnostics, Inc. is a neurodiagnostic company commercializing a breakthrough, first-in-class, proprietary blood test for the diagnosis and treatment monitoring of Major Depressive Disorder (MDD). The company's products are derived from a proprietary Human Biomarker Library(TM) and Biomarker Hyper-mapping (BHyperMap(TM) )technology. Ridge intends to develop a comprehensive neuropsychiatric disease diagnostic platform. Ridge Diagnostics testing services are provided through its CLIA certified laboratory in North Carolina, and it is developing a kit version for future distribution. The company is located in San Diego, CA and Research Triangle Park, NC.
CONTACT: Lonna J Williams, CCO of Ridge Diagnostics, Inc., 1-877-743-4301
Web site: http://www.ridgedx.com/